Amivantamab in advanced non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry Francesco Passiglia, Antonio Passaro, Eleonora Gariazzo, Michele Montrone, Giulia Pasello, Marcello Tiseo, Marco Russano, Fabrizio Citarella, Lucia Anna Muscarella, Daniele Pozzessere, Emilio Bria, Elisa Roca, Giulio Cerea, Alessandro Russo, Salvatore Grisanti, Alessandra Bulotta, Antonello Veccia, Federica Biello, Giuseppe Lo Russo, Sara Pilotto, Carlo Genova, Diego Cortinovis, Gabriele Minuti, Giulia Meoni, Stefania Gori, Maria Lucia Reale, Alberto Pavan, Matteo Ramundo, Francesco Grossi, Hector Soto Parra, Vieri Scotti, Tiziana Vavalà, Claudio Sini, Concetta Sergi, Giacomo Pelizzari, Rita Chiari, Brigida Stanzione, Adolfo Favaretto, Francesco Leone, Anna Cecilia Bettini, Maria Pagano, Luca Tondulli, Luca Toschi, Gaetano Lacidogna, Chiara Bennati, Silvia Catanese, Umberto Malapelle, Diana Giannarelli, Silvia Novello Cancer, 2026 Background The treatment landscape for metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion ( ex20ins ) is rapidly evolving, with the development of specific targeted therapies. The bispecific antibody amivantamab is the new standard of care for this population but real‐world safety and efficacy data are lacking. Methods This is a multicenter, retrospective, observational study conducted on advanced NSCLC patients harboring EGFRex20ins who were included within the ATLAS Italian real‐world registry between January and December 2024. Clinical‐pathological features, treatment effectiveness, and safety outcomes were retrospectively collected and analyzed. Results A total of 119 advanced NSCLC patients harboring EGFRex20ins mutations were included. Seventy‐six (63.9%) and 24 (20.2%) received first‐line platinum‐based chemotherapy with or without immunotherapy, respectively. Overall 64 of 119 patients received single agent amivantamab in the subsequent lines. Treatment‐related adverse events (TRAEs) of any grade and grade 3–4 were reported in 68.8% and 10.9%, respectively, including skin rash (56%, G3 9.4%), asthenia (9%), peripheral edema (8%), and infusion‐related reactions (9.4%, G3 1.5%). Dose interruptions, reductions, and discontinuations due to TRAEs occurred in 20.3%, 12.5%, and 3.1% patients, respectively. The objective response rate was 37.5%, the DCR was 66.2%, the median progression‐free survival (mPFS) was 9.6 months, and the median overall survival was 16.9 months under amivantamab. Among the 23 patients with brain metastasis, 13% achieved a partial intracranial (ic) response and 43.5% a stable disease. The ic mPFS was 11.6 months. Conclusion This data confirms the efficacy and safety profile of amivantamab observed in the CHRYSALIS trial, showing a meaningful clinical benefit in a heavily pretreated real‐world population.
Braf-mutant metastatic non–small-cell lung cancer: Real world data from the Italian biomarker atlas database Claudio Sini, Alessandro Russo, Diego Cortinovis, Lucia Anna Muscarella, Marcello Tiseo, Emilio Bria, Salvatore Grisanti, Pierluigi Piovano, Antonello Veccia, Lorenzo Antonuzzo, Fabrizio Citarella, Sara Pilotto, Maria Lucia Reale, Daniele Pignataro, Elisa Roca, Lorenzo Calvetti, Pamela Pizzutilo, Gabriele Minuti, Giacomo Pelizzari, Greta Alì, Anna Bettini, Alberto Pavan, Diego Signorelli, Serena Ricciardi, Giulia Meoni, Concetta Sergi, Carlo Genova, Vieri Scotti, Tiziana Vavalà, Stefania Gori, Giulia Pasello, Paolo Pedrazzoli, Rita Chiari, Alessandro D’Aveni, Roberta Buosi, Luca Toschi, Hector Soto Parra, Lucio Buffoni, Brigida Stanzione, Cinzia Ortega, Cristina Zannori, Diana Giannarelli, Umberto Malapelle, Silvia Novello, Francesco Passiglia, Editta Baldini European Journal of Cancer, 2026 BACKGROUND: BRAF mutations identify a small subgroup of patients (pts) with non-small cell lung cancer (NSCLC). Dabrafenib/trametinib (D/T) combination is associated with high response rates and durable anti-tumor activity in BRAF-V600-mutants. Several open questions still remain unanswered in clinical practice, including the efficacy of treatments based on clinical and molecular characteristics, the activity in patients with brain metastases, the optimal sequence with immunotherapy-based therapies. Here we present outcomes among advanced BRAF-mutant NSCLC patients from the Italian ATLAS registry. METHODS: Patients with metastatic BRAF-mutated NSCLC were included. Clinical-pathological features, treatment effectiveness and safety outcomes were retrospectively collected from the Italian real-world ATLAS registry. RESULTS: A total of 244 BRAF-mutated NSCLC pts were enrolled, including 70 % V600E mutations. The median PFS of first line D/T was 19.8 months (95 % CI: 10.7-29.0), with a 2-year OS rate of 65.4 % and a PFS2 of 6.6 months (95 % CI: 0-14.3). The activity of D/T differs among sex (mPFS was 13.6 mos and 25.3 mos and 2-yr OS rate were 54.9 % and 72.3 % in males and females, respectively) and smoking status (mPFS was 18.4 mos, 25.6 mos and 24 mos in never, former and current smokers, respectively). Concomitant MET amplification was associated with a shorter median PFS (mPFS was 13.6 mos vs. 44.3 mos with and without MET amplification respectively) in pts treated with D/T as 1st line. CONCLUSIONS: These data confirm the efficacy and safety of first line D/T in BRAF V600E-mutated pts in the real-world setting consistently with prior studies, suggesting a differential activity among key clinical-molecular subgroups.
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry Francesco Passiglia, Maria Lucia Reale, Giulia Pasello, Giuseppe Viscardi, Ilaria Attili, Francesca Mazzoni, Domenico Galetta, Chiara Catania, Kallopi Andrikou, Alessandro Russo, Tiziana Vavala, Alessandra Bulotta, Lorenzo Calvetti, Anna Maria Carta, Salvatore Grisanti, Sabrina Mariotti, Giulia La Cava, Alessandra Dodi, Vieri Scotti, Teresa Del Giudice, Gabriele Minuti, Elio Gregory Pizzutillo, Rita Chiari, Carminia Maria Della Corte, Carlo Genova, Giuseppe Lo Russo, Daniele Pignataro, Daniele Pozzessere, Elisa Roca, Luca Toschi, Chiara Bennati, Gloria Borra, Anna Bettini, Adolfo Favaretto, Alain Gelibter, Stefania Gori, Fabrizio Tabbò, Maria Pagano, Alberto Pavan, Lorenzo Belluomini, Luca Tondulli, Concetta Sergi, Brigida Stanzione, Umberto Malapelle, Silvia Novello, Emilio Bria Oncologist, 2026 Background This study describes clinical characteristics, treatment patterns as well as safety outcomes of NSCLC patients harboring PD-L1 ≥ 50% who received adjuvant atezolizumab within the Italian real-world scenario. Methods Patients with surgically resected NSCLC harboring EGFR/ALK wild type disease and PD-L1 TPS ≥ 50%, who received at least one cycle of adjuvant atezolizumab were included. Clinical-pathological and molecular data, safety and efficacy outcomes were collected from the Italian ATLAS real-world registry. Results A total of 132 patients were included across 45 Italian centers between July 2022 and August 2024. Lobectomy was performed in 81.1% of cases, with 8.3% pathological stage IIA, 40.2% stage IIB, 43.9% stage IIIA, and 7.6% stage IIIB, according to the eighth TNM staging edition. The median number of atezolizumab cycles was 12.5 (range: 1-20). Treatment related adverse events (TRAEs) during atezolizumab were reported in 44 patients (33.3%), including 11 (8.3%) who experienced multiple TRAEs. Grade ≥ 3 TRAEs were reported in 21 cases (15.9%), leading to treatment discontinuation in 18 (13.6%). The median time to the first onset of TRAEs was 89 days (range: 3-390 days). 15 patients experienced a disease recurrence, including 6 locoregional-only and 9 distant relapses, with a median time since surgery of 13.3 months. Conclusion This study showed that the safety profile of adjuvant atezolizumab outside of a clinical trial context was comparable to the IMPower-010 study, highlighting the value of the Italian ATLAS registry as source of real-word evidence to optimize the clinical management of NSCLC patients.
Bone metastases in NSCLC: Modern paradigms in management and supportive care Gabriele Minuti, Giorgia Pasqualini, Alice Avancini, Niccolò Giaj-Levra, Francesca Colonese, Alessandro Di Federico, Alessandra Fozza, Michele Montrone, Emanuela Olmetto, Edoardo Pastorello, Maria Lucia Reale, Silvia Teresa Riva, Elisa Roca, Claudio Sini, Giuseppe Viscardi, Sara Pilotto, Francesco Passiglia Cancer Treatment Reviews, 2026 HighlightsBone metastases occur in up to 60% of NSCLC patients during disease progression Bone-targeted agents reduce SREs and may enhance immunotherapy efficacy Radiotherapy is key for pain control and spinal stability in bone metastases Exercise is safe and may preserve bone health in patients with bone metastases Nutritional support helps preserve muscle mass and improves treatment tolerance Abstract Bone metastases (BoMs) are a frequent complication in advanced non-small-cell lung cancer (NSCLC), affecting approximately one third of patients at diagnosis and 35-60% during the disease course.BoMs increase the risk of skeletal-related events (SREs), which have a detrimental impact on prognosis, performance status, and quality of life (QoL).Management of BoMs in NSCLC requires a multimodal approach.Although systemic anti-cancer therapies remain the cornerstone, the optimal management of BoMs in NSCLC also encompasses bone-targeted agents (BTAs) such as bisphosphonates and denosumab, local treatments including radiotherapy and surgical interventions, and supportive care strategies aimed at preventing SREs, alleviating pain, preserving mobility, and maintaining QoL.This review provides an updated overview of best practices for managing BoMs in NSCLC, covering diagnostic work-up, therapeutic strategies, and the growing role of multidisciplinary care.It emphasizes the importance of supportive interventions, including nutrition and physical activity, to optimize outcomes in the era of targeted and immune-based therapies, alongside comprehensive simultaneous care.
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study Igor Gomez-Randulfe, Federico Monaca, Ornella Cantale, Maria Lucia Reale, Loredana Mrak, Lodovica Zullo, Sofia Silva Diaz, Marta Zaragoza Bueno, Marya Alejandra Maridueña Moreno, Charlotte Davis, Samantha Cox, Daniel Lee, Riyaz Shah, Tom Geldart, Javier Baena, Jose Carlos Benitez, M.A. Rosario Garcia Campelo, Jordi Remon, David Planchard, Domenico Galetta, Marcello Tiseo, Diego Cortinovis, Giulio Metro, Emilio Bria, Francesco Passiglia, Silvia Novello, Raffaele Califano Lung Cancer, 2025
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database Maria Lucia Reale, Daniela Scattolin, Antonio Vitale, Francesco Passiglia, Salvatore Grisanti, Marianna Macerelli, Domenico Galetta, Claudio Sini, Gabriele Minuti, Fabrizio Citarella, Elisa Roca, Francesco Agustoni, Alessandra Dodi, Diego Cortinovis, Lorenzo Belluomini, Serena Ricciardi, Antonello Veccia, Elio Gregory Pizzutilo, Vieri Scotti, Greta Alì, Francesca Mazzoni, Alessandro Russo, Daniele Pignataro, Alessandra Bulotta, Pierluigi Piovano, Concetta Sergi, Anna Bettini, Carlo Genova, Alberto Pavan, Hector José Soto Parra, Cinzia Ortega, Daniele Pozzessere, Tiziana Vavalà, Rita Chiari, Cristina Zannori, Alessandro D’Aveni, Giulia Meoni, Diana Giannarelli, Umberto Malapelle, Silvia Novello, Emilio Bria, Giulia Pasello Lung Cancer, 2025
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study Alice Avancini, Niccolò Giaj-Levra, Gabriele Minuti, Giorgia Pasqualini, Francesca Colonese, Alessandro Di Federico, Alessandra Fozza, Michele Montrone, Emanuela Olmetto, Edoardo Pastorello, Maria Lucia Reale, Silvia Teresa Riva, Elisa Roca, Claudio Sini, Giuseppe Viscardi, Francesco Passiglia, Sara Pilotto Lung Cancer, 2025 INTRODUCTION: The current study aims to investigate the current practice of bone metastasis management in patients with non-small cell lung cancer. METHODS: An online questionnaire was administered to 92 oncologists. A survey was developed and revised by dedicated experts and was composed of five sections: i) general and work characteristics, ii) diagnostic issues, ii) bone-targeted agents issues, iii) radiotherapy issues, and iv) supportive care issues. Descriptive statistics was applied. RESULTS: The 18F-FDG PET is the preferred evaluation for skeletal assessment for both patients with (62 %) and without (54 %) bone lesions at the CT scan; MRI (63 %) and 18F-FDG PET (61 %) are the most chosen radiographic assessments when a bone oligoprogression is suspected. The number of bone metastatic lesions was the main factor considered when deciding whether to start bone-targeted agents (57 %). In choosing between bone-targeted agents, renal toxicity was the most considered factor (62 %). Over half of the participants did not stop the systemic treatment during stereotactic radiotherapy (68 %) and considered re-irradiation on progressive bone metastases at least 6 months after prior radiotherapy (55 %). Overall, 64 % and 41 % of participants assessed patients' body weight and physical activity, respectively. Oral nutritional supplements or a specific diet were recommended by 34 % and 46 % of clinicians; 40 % of them also advised their patients to increase their physical activity levels, while 54 % were worried that exercise might increase the risk of skeletal-related adverse events. CONCLUSIONS: Lung-cancer dedicated clinicians pay great attention to bone metastases-related diagnostic, bone-targeted agents, and radiotherapy issues, whereas the integration of supportive care approaches seem less standardized.
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) Francesco Passiglia, Angela Listì, Paolo Bironzo, Alessandra Merlini, Federica Benso, Francesca Napoli, Francesca Alice Barbu, Vanessa Zambelli, Fabrizio Tabbò, Maria Lucia Reale, Claudio Sini, Elisa Roca, Paola Adriana Taveggia, Francesca Simionato, Lucio Buffoni, Laura Mazilu, Vito Barbieri, Daniele Pignataro, Antonio Araujo, Luis Paz-Ares, Enriqueta Felip, Nevena Secen, Alina Comanescu, Kleida Mati Ramizi, Anna Cecilia Bettini, Vieri Scotti, Helena Linardou, Katja Mohorcic, Giulia Meoni, Diana Giannarelli, Marco Volante, Umberto Malapelle, Stefania Vallone, Giorgio Scagliotti, Luisella Righi, Silvia Novello Journal of Thoracic Oncology, 2025
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows” Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, Andrea Mogavero, Valerio Maria Napoli, Edoardo Garbo, Massimiliano Cani, Antonio Ungaro, Maria Lucia Reale, Alessandra Merlini, Enrica Capelletto, Paolo Bironzo, Mario Levis, Umberto Ricardi, Silvia Novello, Francesco Passiglia Cancer Treatment Reviews, 2025
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database M.L. Reale, F. Passiglia, F. Cappuzzo, G. Minuti, M. Occhipinti, A. Bulotta, A. Delmonte, C. Sini, D. Galetta, E. Roca, G. Pelizzari, D. Cortinovis, E. Gariazzo, S. Pilotto, F. Citarella, E. Bria, P. Muscolino, D. Pozzessere, A. Carta, D. Pignataro, L. Calvetti, F. Leone, M. Banini, C. Di Micco, E. Baldini, A. Favaretto, U. Malapelle, S. Novello, G. Pasello, M. Tiseo ESMO Open, 2024 BACKGROUND: Mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare alteration in non-small-cell lung cancer (NSCLC), occurring in about 3%-4% of cases. Here we report disease and patient characteristics, and efficacy and tolerability of MET inhibitors among advanced METex14 NSCLC patients from the Italian real-world registry ATLAS. MATERIALS AND METHODS: Clinical-pathological and molecular data, and treatment efficacy/tolerability outcomes were retrospectively collected from the ATLAS registry. RESULTS: From July 2020 to July 2023 a total of 146 METex14 advanced NSCLC patients were included across 27 Italian centers. Median age was 74 years, and most patients were male (52%), with an Eastern Cooperative Oncology Group performance status < 2 (72%) and adenocarcinoma subtype (83%). One hundred and twenty-five out of 146 (86%) patients received at least one line of systemic anticancer therapy. Fifty-six (38%) were treated with capmatinib and 34 (23%) with tepotinib. 29% and 52% of them received targeted treatment in the first and second line, respectively. In the cohort of patients treated with MET inhibitors, the response rate (RR) was 37% (33% in previously treated patients and 46% in treatment-naïve) with a disease control rate of 62%. With a median follow-up of 10.8 months, progression-free survival was 6.6 months [95% confidence interval (CI) 4.3-8.3 months] and overall survival was 10.7 months (95% CI 7.2-19.3 months). In patients with measurable brain metastases (17 cases), the intracranial RR was 41%. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 12% of patients with grade 3 peripheral edema in 7% of cases. A fatal adverse reaction occurred in one patient due to pneumonitis. TRAEs-related dose reduction and discontinuation were reported in 6% and 8% of cases, respectively. CONCLUSION: Capmatinib and tepotinib represent an effective treatment option in NSCLC patients with METex14. Real-world efficacy outcomes are worse than those reported in prospective clinical trials. Their activity is more pronounced in the treatment-naïve population, suggesting that this is the right setting in the management of patients with METex14.
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database Umberto Malapelle, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Maria Lucia Reale, Diego Cortinovis, Filippo Fraggetta, Domenico Galetta, Edoardo Garbo, Paolo Graziano, Fabio Pagni, Giulia Pasello, Pierluigi Piovano, Sara Pilotto, Marcello Tiseo, Carlo Genova, Luisella Righi, Giancarlo Troncone, Silvia Novello Lung Cancer, 2024
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy Vito Longo, Carminia Maria Della Corte, Alessandro Russo, Francesca Spinnato, Francesca Ambrosio, Riccardo Ronga, Antonella Marchese, Teresa Del Giudice, Concetta Sergi, Francesca Casaluce, Marina Gilli, Michele Montrone, Valerio Gristina, Vincenzo Sforza, Maria Lucia Reale, Raimondo Di Liello, Alberto Servetto, Helga Lipari, Claudio Longhitano, Laura Vizzini, Anna Manzo, Antonella Cristofano, Loretta Paolelli, Annalisa Nardone, Simona De Summa, Antonella Perrone, Carmela Bisceglia, Caterina Derosa, Valerio Nardone, Giuseppe Viscardi, Domenico Galetta, Fabiana Vitiello Frontiers in Immunology, 2024
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program Francesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, Giulia Pasello, Gabriele Minuti, Alessandra Bulotta, Domenico Galetta, Giacomo Pelizzari, Claudio Sini, Emilio Bria, Elisa Roca, Sara Pilotto, Carlo Genova, Giulio Metro, Fabrizio Citarella, Rita Chiari, Diego Cortinovis, Angelo Delmonte, Alessandro Russo, Marcello Tiseo, Giulio Cerea, Annamaria Carta, Vieri Scotti, Tiziana Vavalà, Marta Brambilla, Lucio Buffoni, Roberta Buosi, Chiara Catania, Stefania Gori, Salvatore Grisanti, Francesco Agustoni, Edoardo Garbo, Umberto Malapelle, Silvia Novello Lung Cancer, 2024
Repositioning PARP inhibitors in the treatment of thoracic malignancies Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, Elena Parlagreco, Francesca Jacobs, Angela Listì, Luisella Righi, Paolo Bironzo, Silvia Novello, Giorgio Vittorio Scagliotti Cancer Treatment Reviews, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics Laura Mezquita, Isabel Preeshagul, Edouard Auclin, Diana Saravia, Lizza Hendriks, Hira Rizvi, Wungki Park, Ernest Nadal, Patricia Martin-Romano, Jose C. Ruffinelli, Santiago Ponce, Clarisse Audigier-Valette, Simona Carnio, Felix Blanc-Durand, Paolo Bironzo, Fabrizio Tabbò, Maria Lucia Reale, Silvia Novello, Matthew D. Hellmann, Peter Sawan, Jeffrey Girshman, Andrew J. Plodkowski, Gerard Zalcman, Margarita Majem, Melinda Charrier, Marie Naigeon, Caroline Rossoni, AnnaPaola Mariniello, Luis Paz-Ares, Anne Marie Dingemans, David Planchard, Nathalie Cozic, Lydie Cassard, Gilberto Lopes, Nathalie Chaput, Kathryn Arbour, Benjamin Besse European Journal of Cancer, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients Umberto Malapelle, Francesco Passiglia, Chiara Cremolini, Maria Lucia Reale, Francesco Pepe, Pasquale Pisapia, Antonio Avallone, Diego Cortinovis, Alfonso De Stefano, Matteo Fassan, Gabriella Fontanini, Domenico Galetta, Calogero Lauricella, Angela Listì, Fotios Loupakis, Fabio Pagni, Filippo Pietrantonio, Sara Pilotto, Luisella Righi, Andrea Sartore Bianchi, Hector Soto Parra, Marcello Tiseo, Michela Verzè, Giancarlo Troncone, Silvia Novello European Journal of Cancer, 2021
Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center Maristella Bungaro, Valentina Bertaglia, Marco Audisio, Elena Parlagreco, Chiara Pisano, Valeria Cetoretta, Irene Persano, Francesca Jacobs, Chiara Baratelli, Lorena Consito, Maria Reale, Fabrizio Tabbò, Paolo Bironzo, Giorgio Scagliotti, Silvia Novello Exploration of Targeted Anti Tumor Therapy, 2021
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit Maria Lucia Reale, Paolo Bironzo, Valentina Bertaglia, Erica Palesandro, Gianmarco Leone, Fabrizio Tabbò, Maristella Bungaro, Marco Audisio, Annapaola Mariniello, Simonetta G. Rapetti, Rosario F. Di Stefano, Elisa Artusio, Enrica Capelletto, Paola Sperone, Adriana Boccuzzi, Marco Calandri, Alberto Perboni, Umberto Malapelle, Francesco Passiglia, Silvia Novello Frontiers in Oncology, 2020
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018 Pasquale Lombardi, Laura Marandino, Emmanuele De Luca, Clizia Zichi, Maria Lucia Reale, Daniele Pignataro, Rosario F. Di Stefano, Eleonora Ghisoni, Annapaola Mariniello, Elena Trevisi, Gianmarco Leone, Leonardo Muratori, Anna La Salvia, Cristina Sonetto, Francesco Leone, Massimo Aglietta, Silvia Novello, Giorgio V. Scagliotti, Francesco Perrone, Massimo Di Maio Critical Reviews in Oncology Hematology, 2020
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients Maria Lucia Reale, Rita Chiari, Marcello Tiseo, Fabiana Vitiello, Fausto Barbieri, Diego Cortinovis, Giovanni Luca Ceresoli, Giovanna Finocchiaro, Gianpiero Diego Romano, Pier Luigi Piovano, Alessandro Del Conte, Gloria Borra, Francesco Verderame, Vieri Scotti, Daniela Nonnis, Domenico Galetta, Concetta Sergi, Maria Rita Migliorino, Giuseppe Tonini, Fabiana Cecere, Rossana Berardi, Maria Simona Pino, Olga Martelli, Alain Gelibter, Annamaria Carta, Emanuela Vattemi, Maria Pagano, Alessandro Zullo, Silvia Ferrari, Antonio Rossi, Silvia Novello Lung Cancer, 2020
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018 Maria Lucia Reale, Emmanuele De Luca, Pasquale Lombardi, Laura Marandino, Clizia Zichi, Daniele Pignataro, Eleonora Ghisoni, Rosario F. Di Stefano, Annapaola Mariniello, Elena Trevisi, Gianmarco Leone, Leonardo Muratori, Anna La Salvia, Cristina Sonetto, Paolo Bironzo, Massimo Aglietta, Silvia Novello, Giorgio V. Scagliotti, Francesco Perrone, Massimo Di Maio Lung Cancer, 2020
68Ga-PSMA Uptake in Fibrous Dysplasia Maria Lucia Reale, Consuelo Buttigliero, Marcello Tucci, Roberto Giardino, Carlo Poti Clinical Nuclear Medicine, 2019
